There is also a need to improve multidisciplinary care, according to Ekene Enemchukwu, MD. Knowledge about genitourinary syndrome of menopause (GSM) and the benefits of vaginal estrogen is lacking, ...

Combination of BWL and ultrasonic propulsion effectively fragments and repositions small renal stones in awake patients without anesthesia. The procedure achieved a 71% success rate in reducing stone ...

Merrill discusses the evolving non–muscle invasive bladder cancer treatment space. Expanded access programs (EAPs), such as a recently FDA-authorized EAP in which ImmunityBio is partnering with the ...

A panelist discusses how both the ARCHES and ARANOTE trials demonstrated significant improvements in radiographic progression-free survival with their respective novel hormonal therapies (enzalutamide ...

A panelist discusses how the ARCHES and ARANOTE trials differ in their fundamental design elements, with ARCHES evaluating enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in ...

Bipolar resection and enhanced imaging are preferred for NMIBC assessment, reflecting a trend towards advanced diagnostic tools. Pembrolizumab offers a distinct safety profile for BCG-unresponsive ...

Cleveland Clinic performed the first transcontinental robot-assisted HIFU focal therapy for prostate cancer, connecting Ohio and Abu Dhabi. The procedure involved remote operation by Dr. Ruben ...

Please share your concluding thoughts about the recent progress and future outlook of NMIBC.

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC. Data from the phase 3 TALAPRO-2 trial (NCT03395197) showed that the combination of enzalutamide ...

If they are FDA approved, what impact are the novel delivery systems likely to have on patients’ quality of life? Treatment adherence?

“I think the great thing about Cost Plus Drugs is that, as we mentioned, it's simple, but it's also price transparent," says Raymond Xu, MD. “I think the great thing about Cost Plus Drugs is that, as ...

Experts discuss their expectations regarding the uptake of new treatments in clinical practice for non–muscle-invasive bladder cancer and other relevant conditions.